Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04380779
NCT04380779
Completed
Not Applicable

Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)

Manuel Monreal1 site in 1 country2,430 target enrollmentApril 13, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
Manuel Monreal
Enrollment
2430
Locations
1
Primary Endpoint
Bleeding events and complications
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The main objectives are:

  • To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses.
  • To identify variables associated to higher risk of bleeding.
Registry
clinicaltrials.gov
Start Date
April 13, 2020
End Date
October 13, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Manuel Monreal
Responsible Party
Sponsor Investigator
Principal Investigator

Manuel Monreal

Professor of Internal Medicine

Foundation for the study of VTE diseases. (FUENTE)

Eligibility Criteria

Inclusion Criteria

  • •Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses.
  • •Admission to hospital.

Exclusion Criteria

  • •Patients treated with ECMO (Extracorporeal membrane oxygenation).

Outcomes

Primary Outcomes

Bleeding events and complications

Time Frame: 30 days

Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Study of Hemostasis in Case of Severe COVID-19COVID-19 Infection
NCT04359992University Hospital, Strasbourg, France50
Recruiting
Not Applicable
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
NCT05803395Gruppo Italiano Malattie EMatologiche dell'Adulto954
Recruiting
Not Applicable
Covid-19 in Hematological MalignanciesCOVID-19 Infection in Hematological Malignancies Patients
NCT04733729Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne3,000
Completed
Not Applicable
Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) PatientsCovid19
NCT04982263Sohag University125
Terminated
Phase 2
Enzalutamide Treatment in COVID-19COVID-19Corona Virus Infection
NCT04475601Andreas Josefsson42